Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
tubeless insulin pumpmedical
A tubeless insulin pump is a small, wearable device that delivers programmed doses of insulin directly through a patch on the skin, without the external tubing found on traditional pumps. For investors, it matters because these devices can increase patient convenience and adherence, potentially expanding market size, driving recurring sales of disposable pods and supplies, and influencing reimbursement and regulatory risk in the diabetes-care market—similar to how cordless tools changed demand compared with corded models.
insulin pumpmedical
A small wearable medical device that delivers measured doses of insulin automatically or on demand to help people with diabetes regulate their blood sugar, often replacing multiple daily injections. Investors care because these devices combine hardware, software and supplies to create recurring revenue, are subject to regulatory approval and reimbursement decisions, and can change competitive dynamics in a large, growing healthcare market much like a smartphone platform reshapes accessory sales.
insulin management systemmedical
An insulin management system is a combination of devices and software that helps people with diabetes monitor blood sugar and deliver the right amount of insulin automatically or with guidance—think of it as a smart thermostat for glucose. Investors care because these systems can drive steady device and subscription revenue, reduce long-term healthcare costs, and face regulatory and reimbursement hurdles that affect adoption and market size.
subcutaneous drugsmedical
Subcutaneous drugs are medicines formulated to be injected just under the skin into fatty tissue, often delivered with a syringe or an auto-injector for at-home use. For investors, this matters because subcutaneous delivery can make treatments more convenient and less costly to administer than hospital-only options, potentially boosting patient uptake, widening the market, and changing manufacturing and reimbursement dynamics—similar to shifting from a hospital drip to a simple home shot.
automated insulin delivery systemmedical
An automated insulin delivery system is a device that automatically monitors blood sugar levels and adjusts insulin delivery without needing manual input. Think of it as a smart thermostat that keeps a room’s temperature just right, ensuring stable levels. For investors, such systems represent advances in healthcare technology that can improve quality of life and potentially reduce long-term medical costs.
continuous glucose monitormedical
A continuous glucose monitor is a small device worn on the body that constantly tracks blood sugar levels throughout the day and night. It provides real-time data, helping individuals manage conditions like diabetes more effectively. For investors, advancements in this technology can signal growth opportunities in healthcare and medical device markets, reflecting broader trends in health technology innovation.
ACTON, Mass.--(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time).
The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com.
